Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)

New parameters or methods, such as ablation index, have been developed for the quantification of high-frequency energy used in pulmonary vein isolation, but there is no known method for atrial fibrillation considering individual differences in atrial tissue. The atrium is only 1/3 of the thickness of the ventricle and is thinner in women and older than men or young people.

The aim of this study was to evaluate the efficacy and safety of radiofrequency energy therapy using atrial individual differences. In order to reflect the thickness of the atrium, we will use the unipolar and bipolar maps and the myocardial thickness map using computed tomography (CT) images. To evaluate the efficacy and safety of energy titration therapy by random assignment of high frequency energy therapy group, CT image application high frequency energy therapy group, and existing empirical high frequency therapy group.

Study Overview

• Status: Recruiting
• Conditions: Paroxysmal Atrial Fibrillation
• Intervention / Treatment: Procedure: Unipolar voltage subtraction map guided PV isolation group; Procedure: CT myocardial thickness map guided PV isolation group; Procedure: Empirical PV isolation group

Detailed Description

A. Study design

1. Prospective randomization (Unipolar voltage subtraction map guided PV(pulmonary vein) isolation group vs. CT myocardial thickness map guided PV isolation group vs. Empirical PV isolation group )
2. Target number of subjects: 480 (160 per group)
3. Rhythm FU : 2012 ACC/AHA/ESC guidelines (Holter monitoring at the baseline, 2 month, and thereafter every 6 months; ECG if the patient has any symptom)
4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines
5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate.

B. Progress and rhythm/ECG follow-up

1. To be performed in accordance with the 2012 ACC/AHA/HRS guidelines for AF management
2. Follow-up at 1 weeks, 3 months, and thereafter every 6-month after procedure.
3. Rhythm control at 3 months, and thereafter every 6-month follow-up with Holter
4. If the patient complains of symptoms, ECG will be performed at any time, and rhythm follow-up will be carried out with a Holter or event recorder.

C. Follow-up All the patients will be followed-up at 1, 3, 6 months, and thereafter every 6 months. If the patient shows any symptom within the clinical study period, patient will visit the outpatient clinic. ECG will be performed at every outpatient visits, and 24-hour Holter or event recording will be performed every 6 months for 2 years, and every year after 2 years (2012 Heart Rhythm Society/EHRA/European Cardiac Arrhythmia Society Expert Consensus Statement guidelines). If atrial fibrillation or atrial tachycardia lasting more than 30 seconds is observed in 12-lead ECG or Holter, it will be evaluated as recurrence. Recurrence within 3 months after the procedure will be classified as early recurrence, and that after 3 months will be classified as clinical recurrence.

• Study Type: Interventional
• Enrollment (Anticipated): 220
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 120-752
    • Recruiting
    • Severance Cardiovascular Hospital, Yonsei University Health System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and ≥20 and ≤80 years of age
2. Left atrium size < 50mm
3. paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug.
4. Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction)

Exclusion Criteria:

1. Patients with persistent or permanent atrial fibrillation
2. Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected
3. Patients with severe renal impairment or CT imaging difficulty using contrast media
4. Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery
5. Patients with active internal bleeding
6. Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs
7. Patients with valvular atrial fibrillation (mitral stenosis >grade 2, mechanical valve, mitral valvuloplasty)
8. Patients with a severe comorbid disease
9. Expected survival < 1 year
10. Drug addicts or alcoholics
11. Patients who cannot read the consent form (illiterates, foreigners, etc.)
12. Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Unipolar voltage subtraction map guided PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury; Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture; the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes); Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map; Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure and Ablation time, and perfusion saline dose; Rhythm follow-up after the procedure in accordance with the study design.	Procedure: Unipolar voltage subtraction map guided PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury; Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture; the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes); Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map; Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure and Ablation time, and perfusion saline dose; Rhythm follow-up after the procedure in accordance with the study design.
Experimental: CT myocardial thickness map guided PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury.; Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.; Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map; Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure time, Ablation time, and perfusion saline dose; Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.	Procedure: CT myocardial thickness map guided PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury.; Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.; Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map; Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure time, Ablation time, and perfusion saline dose; Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Active Comparator: Empirical PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury.; The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure time, Ablation time, and perfusion saline dose; Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.	Procedure: Empirical PV isolation group; Pulmonary vein isolation will be performed using a radiofrequency catheter; Esophageal temperature will be monitored to prevent esophageal injury.; The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.; Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection; Evaluate time to complete isolation after additional ablation; Evaluation of Procedure time, Ablation time, and perfusion saline dose; Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety evaluation: Procedure-related cardiac complication rate	including open cardiac surgery, cerebral infarction, pericardial effusion or cardiac tamponade, hematoma in the inguinal puncture site and vascular complications within 30 days post procedure.	within 30 days post procedure
Efficacy evaluation: clinical recurrence rate	Defined as atrial fibrillation or atrial tachycardia > 30 sec after 3 months within 1 year; based on the 2012 ACC/AHA/HRS guidelines, 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms	Within 1 year after 3 months of procedure
Efficacy evaluation: Major cardiovascular event rate	death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure	immediate after procedure
Efficacy evaluation: Major cardiovascular event rate	death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure	12 months after procedure

Secondary Outcome Measures

Outcome Measure	Time Frame
Comparison of procedure time	immediate after procedure
Comparison of ablation time	immediate after procedure
Comparison of hospitalization period	immediate after procedure
Comparison of re-hospitalization rate after the procedure	12 months after procedure
Comparison of number of electrical cardioversion after the procedure	12 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	1 week after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	3 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	6 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	12 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	18 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	24 months after procedure
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate	36 months after procedure
Comparison of re-hospitalization rate after the procedure	1 week after procedure
Comparison of re-hospitalization rate after the procedure	3 months after procedure
Comparison of re-hospitalization rate after the procedure	6 months after procedure
Comparison of re-hospitalization rate and number of electrical cardioversion after the procedure	18 months after procedure
Comparison of re-hospitalization rate after the procedure	24 months after procedure
Comparison of re-hospitalization rate after the procedure	36 months after procedure
Comparison of number of electrical cardioversion after the procedure	1 week months after procedure
Comparison of number of electrical cardioversion after the procedure	3 months after procedure
Comparison of number of electrical cardioversion after the procedure	6 after procedure
Comparison of number of electrical cardioversion after the procedure	18 months after procedure
Comparison of number of electrical cardioversion after the procedure	24 months after procedure
Comparison of number of electrical cardioversion after the procedure	36 months after procedure

Collaborators and Investigators

• Sponsor: Yonsei University

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2021
• Primary Completion (Anticipated): April 1, 2024
• Study Completion (Anticipated): April 1, 2024

Study Registration Dates

• First Submitted: April 8, 2019
• First Submitted That Met QC Criteria: April 9, 2019
• First Posted (Actual): April 11, 2019

Study Record Updates

• Last Update Posted (Actual): January 12, 2023
• Last Update Submitted That Met QC Criteria: January 11, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Atrial fibrillation; Pulmonary vein isolation
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Atrial Fibrillation
• Other Study ID Numbers: 4-2019-0109

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No